nvestigators in Western countries have reported that patients with both hypercholesterolemia and type 2 diabetes mellitus (DM) have a higher risk of coronary events (ie, acute myocardial infarction and sudden cardiac death) than patients with hypercholesterolemia alone. 1 The incidence of ischemic heart and cerebrovascular diseases (IHD, CVD) in patients with type 2 DM is reported to be high in Japan, 2 so it has been speculated that when hypercholesterolemia is complicated with DM, the risk of IHD (and perhaps CVD) is also increased in Japanese patients, but direct evidence is limited because there have been few large-scale epidemiological surveys. Recently, the J-LIT study reported a relationship between plasma lipid and coronary events, 3 but it is a study of hypercholesterolemic patients and important information about DM (such as glycohemoglobin) was not studied. Furthermore, only individuals aged 69 years or younger were assessed, and no data were available for the elderly; in addition, all patients were medicated with simvastatin. Therefore, it is worthwhile analyzing the data from the Japan Cholesterol and Diabetes Mellitus investigation (Japan-CDM), which was a nationwide observational cohort study of a large number of diabetic individuals who were treated in clinical practice; it was designed to assess the relationship between lipid levels and the incidence of cardiovascular diseases in Japanese diabetic individuals. 4 In Japan, cholesterol-lowering therapy is well established, but evidence from large-scale studies is not available in relation to plasma levels of low-density lipoprotein (LDL) in diabetic individuals, and at the beginning of the present study (2004), atrovastatin was the only Background The respective incidences of ischemic heart and cerebrovascular disease (IHD, CVD) are high in diabetic individuals. Complications of dyslipidemia increase the risk, but direct evidence is limited, so a cohort prospective study (Japan-CDM) was conducted.
strong statin available and it is reported to possibly affect glucose metabolism. 5, 6 In short, such a randomized control study was not run for ethical and practical reasons. In the Japan-CDM, individuals had no history of prior IHD (myocardial infarction or angina pectoris), so we analyzed the incidence of IHD, CVD and arteriosclerosis obliterans (ASO). We also assessed the relationship between the incidence of IHD, CVD and dyslipidemia and its treatment during the study period.
Methods
We recruited diabetic individuals through 40 institutions throughout Japan between September 2004 and March 2005 (Fig 1) . Patients with coronary artery disease, which was defined as previous myocardial infarction, coronary intervention, or confirmed angina pectoris and recent stroke with admission within the past 24 months were excluded, as were patients whose medical records about plasma lipid (total cholesterol, triglyceride and high-density lipoprotein (HDL)-cholesterol) were not provided. Other exclusion criteria were a history or complication of serious heart disease (eg, severe arrhythmia, heart failure, cardiomyopathy, valvular disease, or congenital disease), CVD within the past 24 months, serious hepatic or renal disease, malignant disease, intention to undergo surgery, any illness with a poor prognosis, and judgment by the physician in charge that the patient was not suitable for the study.
The study group comprised 4,014 diabetic individuals enrolled on a consecutive outpatient basis (1,936 women, 2,078 men; M/F ratio 1.073; mean age 67.4±9.5 years, range 35-80). A single-center prospective longitudinal cohort study with an extensive screening program at baseline was carried out. 4 The pursuit rate for 1 year was 98.8%. The group was divided into those with dyslipidemia with or without medication (79.1%, n=3,175; HM: 50.9% are medicated, n=2,043, 28.2%; HN: n=1,132 are not medicated) and those without dyslipidemia (H-: 20.9%, n=839). Primary endpoints were incidence of cardiovascular or CVD (fatal and non-fatal myocardial infarction, and other non-fatal events including unstable angina pectoris, angioplasty, stenting, or coronary artery bypass grafting and stroke). Secondary endpoints were sudden cardiac death other than myocardial infarction, incidence of onset of ASO, CVD mortality, hospitalization because of CVD or arteriosclerosis thrombosis, and all-cause mortality. Events were defined as all of the primary and secondary endpoints. Detailed definitions of each event are shown in Appendix 1. 7 We evaluated the changes in plasma lipid levels, blood glucose and hemoglobinA1c levels measured during the same month of each year. DM and hyperlipidemia, and the progression of diabetic complications (microangiopathy: retinopathy, neuropathy, nephropathy) were also investigated. Lipid levels, adverse events and coronary events were monitored at least annually. The patients were to be treated according to the guidelines of the Japan Atherosclerosis Society (2002): LDL <3.16 mmol/L in diabetic individuals. 8 Each patient was informed of the study purpose, as well as drug efficacy and treatment, and gave written agreement. We used the criteria for the diagnosis of type 2 DM that were established in 1999 by the Japan Diabetes Society (JDS), which are similar to those of the American Diabetes Association. 8, 9 All events (clinical endpoints and severe adverse events) during the study period reported by local physicians were checked by members of then organizing committee and endpoints adjudication was also confirmed annually by the organizing committee. The study was approved by external data and safety monitoring boards, and by the institutional review boards at all hospitals.
Statistical Analysis
The results are presented as mean ± SD. All statistical analyses were performed using JMP software (version 6, SAS Institute Inc, Cary, NC, USA). The incidence of events was age-standardized by direct method, in which our whole sample population was supposed as a standard population. The incidence was analyzed in relation to lipid levels on registration, and the differences among categorical variables were assessed by the Mantel-Haenszel chi-square test. Values of p<0.05 were considered to indicate statistical significance. The relative risk and its 95% confidence interval (CI) were calculated using logistic regression analyses with adjustment for baseline characteristics such as sex and age. As a result, adjusted odds ratios (OR) were calculated.
Results
Patients' profiles are shown in Fig 1 and Table 1 . Triglyceride levels were higher in younger diabetic individuals than in the older ones. Table 2 shows the detailed information of events occurring during the first year. There were 85 vascular events and 4 deaths of other etiologies. IHD and CVD occurred in 0.82% and 0.67%, respectively, in the first year (Tables 2,3 ). When the events were divided according to the LDL level at registration, the lowest incidence was in individuals with LDL-cholesterol <2.11 mol/L, especially in males after adjustment for age. In other words, 0.45%, 1.56%, 1.78%, 1.91% and 2.34% of IHD or CVD events occurred in males with <2.11, 2.11-2.62, 2.63-3.15, 3.16-3.67, and >3.68 mol/L LDL-cholesterol, respectively, with significant difference after adjustment for age (p=0.032, Fig 2) . However, total events (cardiovascular, cerebrovascular and peripheral vascular disease, congestive heart failure, Table 3 ). Age (>75 years) and complicated hypertension, but not gender, tended to increased the risk of events despite the level of LDL (Figs 2,3, data partially not shown). Interestingly, the patients who were prescribed antihyperlipidemic agents tended to suffer fewer events than the patients who were not being treated, regardless of their LDL levels (Fig 4) . Significant statistical difference was observed in relation to elevated levels of HDL-cholesterol and lower cardiovascular and cerebrovascular events after adjustment for age (p=0.0004; Table 4 , Fig 5) . The OR was 3.97 (95% CI 1.91-8.20, <1.05 mmol/L vs >1.58 mmol/L, p=0.011). The same tendencies were also observed for the total vascular events in males after adjustment for age (p=0.0011, OR 3.01, 95% CI 1.15-4.03, <1.05 mmol/L vs >1.58 mmol/L, p= 0.03) and total events in males after adjustment for age (p=0.0012, OR 2.91, 95% CI 1.11-3.23, <1.05 mmol/L vs >1.58 mmol/L, p=0.041) (Fig 5). Fig 6 compares the frequency of IHD and CVD events reported in a recent, large clinical trial in Japan and in other countries. Subjects with type 2 DM had significantly more IHD events than those without type 2 DM (eg, Hisayama vs JEDIT, J-DCS and J-CDM). The ratio of CVD events was not significantly different. So, the incidence was approximately 2-fold that of the Hisayama study, which is the Japanese-equivalent community cohort study. Interestingly, the frequency is low in J-LIT, based on the assumption that the individuals were 65 years of age, male and diabetic. The significance is the magnitude of the difference of incidence because of their LDL or HDL levels. Ideally, if the patient's LDL or HDL is well controlled, the incidence is comparable with the mean of that in a normal cohort (60 years of age). Compared with the Japanese data, the data available from other countries (particularly that for elderly diabetic individuals) Incidence of total events (cardiovascular, cerebrovascular and peripheral vascular disease, congestive heart failure, sudden death and death by other etiology). *p<0.05; data adjusted for age. show that the incidence of events in Japan is comparable with that in the most well-known community cohort, the Framingham study.
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Discussion
Diabetes is a common cause of morbidity and premature loss of life. 1 People with DM are 4-fold more likely to have IHD as those without DM and IHD accounts for a large proportion of the mortality related to DM. 10, 11 Furthermore, CVD, peripheral vascular disease (such as ASO) and congestive heart failure are reportedly increased in diabetic individuals, especially in elderly Japanese diabetics, compared with individuals without DM. The present study may be 1 of the largest cohort studies carried out for Japanese diabetic individuals with or without hypercholesterolemia. Evidence suggests that even in the absence of preexisting vascular disease, middle-aged people with type 2 DM have a similar risk of IHD to those in Western countries without DM but who have had a myocardial infarction. 12 However, this is not evident in Japan, and the Japan Atherosclerosis Society suggests that the ideal level of LDL in diabetic individuals is <3.16 mmol/L compared with that after a previous myocardial infarction, which is <2.63 mmol/L. 8 The idea of DM as a coronary equivalent has led to widespread changes in the approach to reducing CVD risk in this population, [13] [14] [15] but that may not be the case in Japanese, as the mean LDL level was approximately 3.16 mmol/L in the present study. An issue that concerns many practitioners is the age and levels at which vascular protection strategies should be initiated in people with DM. Recent randomized controlled trials on this topic have included participants older than 70 years of age and 3 large-scale clinical studies of the effect of statins on hyperlipidemic elderly individuals (ie, Prosper (pravastatin), HPS (simvastatin) and ASCOT-LLA) have been reported. [16] [17] [18] In all them hyperlipidemic patients <75 years of age were treated, and the effect of statins on cardiovascular events (including diabetic individuals) were reported. However, the effect was not as large (eg, 16% decrease in IHD without a change of CVD in Prosper) compared with previous studies on the primary and secondary prevention of IHD in diabetic individuals. 15, 19 To date, there are no comparable studies in Japan that we are aware of, so implementation of the results of the present study may potentially lead to a decrease in CVD and IHD by controlling LDL and HDL levels. However, many clinical practice guidelines recommend the application of existing evidence when treating these individuals, so further studies are necessary to elucidate this.
National cholesterol guidelines in several countries recommend using the same therapeutic targets for people with type 2 DM as those recommended for secondary prevention of coronary artery disease. 12 In this respect, all adults with type 2 DM, irrespective of their age, are regarded as being at high risk of fatal or non-fatal coronary events. In 2005, the International Diabetes Federation published global guidelines suggesting that people with type 2 DM should be judged as being at a high risk of developing CVD if they were older than 40 years, even in the absence of preexisting CVD or coronary risk factors. 20 The American Diabetes Association takes a similar approach. 21 The UK National Institute for Health and Clinical Excellence uses risk assessment tables to select individuals with type 2 DM for primary prevention strategies. 22 However, the relationship between age and risk of CVD in people with DM has not been fully elucidated. On the other hand, predictive algorithms created from diabetic cohorts have shown that age is a strong predictor of IHD, but little is known about the absolute risk of these events in younger people with DM. 23 Moreover, the appropriateness of existing age thresholds for the identification of people with DM who are at high risk of CVD is not known. Furthermore, in the present study, gender differences were not observed in relation to the incidence of events. In almost all clinical studies on hyperlipidemic patients, males are reported to suffer more from CVD than females. Although the high incidence in female diabetic individuals has been reported previously, there are few reports of such data in Japan. Furthermore, the incidence in females occurs from the sexagenarian onward.
In the present study patients who were prescribed antihyperlipidemic agents tended to suffer less from CVD or IHD at the same LDL levels. It is possible that medicated patients may be more conscious of their disease and their lifestyle. This is usually advocated in the interpretation of the preventive effect on IHD in postmenopausal women taking hormone replacement therapy (HRT) compared with women without HRT. 24 However, it is also possible that drugs such as statins have a direct atheroprotective effect in patients with DM. Pleiotropic effects of antihyperlipidemic agents are often reported, and this may continue for several years. 25, 26 As the data are insufficient for further analyses, we cannot conclude what might affect the tendency of differences occurring in the incidence between medicated patients and non-medicated patients. However, we intend that this study will be carried out for more than 4 years, as planned.
Conclusion
A relationship was found between all HDL levels, or LDL levels and atherosclerotic events (cardiovascular, cerebrovascular and ASO events) especially in the elderly. The prescribed antihyperlipidemic agents tended to decrease the event ratio without any relationship with lipid levels, which suggests that vascular mechanisms, as well as lipid control, may be responsible for vascular events in diabetic individuals. The present study has the potential to provide evidence for lipid control in diabetic individuals, and may show what is important for the development of hyperlipidemia in the elderly. It also highlights possible future treatments of hyperlipidemia in Japanese diabetic individuals.
